M&A - Sunshine Lake Pharma Co., Ltd.

Form Type: CB/A

Filing Date: 2025-03-11

Corporate Action: Merger

Type: Update

Accession Number: 000110465925022344

Filing Summary: The document is an amendment concerning the tender offer by Sunshine Lake Pharma Co., Ltd. for YiChang HEC ChangJiang Pharmaceutical Co., Ltd. It details the proposed pre-conditional privatization through a merger by absorption. Additionally, the document includes extensions regarding the dispatch of related composite documents and monthly updates pertinent to the privatization process. Key points involve the joint announcements of proposed special dividends, withdrawal of listings, licensing agreements for product developments, and fulfilment of pre-conditions for the transaction. The tender offer commenced on May 10, 2024, with ongoing updates being provided in successive filings.

Document Link: View Document

Form Type: CB/A

Filing Date: 2025-02-11

Corporate Action: Merger

Type: Update

Accession Number: 000110465925011068

Filing Summary: This document is an amendment notification regarding the tender offer of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. It highlights the proposed pre-conditional privatisation of YiChang HEC through a merger by absorption. Details include the initiation date of the tender offer on May 10, 2024, and provide a comprehensive list of joint announcements related to this privatisation plan, covering updates and fulfillments of pre-conditions essential for proceeding with the merger. The document confirms the timing of prior submissions to the SEC, as well as licensing agreements involving Sunshine Lake Pharma. The corporate secretary certifies the accuracy of the information presented.

Document Link: View Document

Form Type: CB/A

Filing Date: 2025-01-10

Corporate Action: Merger

Type: Update

Accession Number: 000110465925002349

Filing Summary: Sunshine Lake Pharma Co., Ltd. is filing an amendment to the tender offer regarding the proposed pre-conditional privatisation of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. The merger will be executed by absorption of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. The filing includes a joint announcement detailing the status of this process, which incorporates proposed special dividends, withdrawal of listing, and resumption of trading updates. This amendment is the 11th in a series of updates on the tender offer, initiated on May 10, 2024, and highlights the legal compliance under various securities regulations. The specific contacts and necessary documents related to the offer are provided, which collectively facilitate the transparency and execution of the described merger activities.

Document Link: View Document